Combined modality therapy for laryngeal cancer with superselective intra-arterial cisplatin infusion and concomitant radiotherapy

Shigenari Taki; Akihiro Homma; Fumiyuki Suzuki; Nobuhiko Oridate; Hiromitsu Hatakeyama; Takatsugu Mizumachi; Satoshi Kano; Jun Furusawa; Tomohiro Sakashita; Naoya Inamura; Daisuke Yoshida; Rikiya Onimaru; Hiroki Shirato; Satoshi Fukuda

doi:10.1007/s10147-011-0308-1

Combined modality therapy for laryngeal cancer with superselective intra-arterial cisplatin infusion and concomitant radiotherapy

Int J Clin Oncol. 2012 Oct;17(5):441-6. doi: 10.1007/s10147-011-0308-1. Epub 2011 Oct 1.

Authors

Shigenari Taki¹, Akihiro Homma, Fumiyuki Suzuki, Nobuhiko Oridate, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Jun Furusawa, Tomohiro Sakashita, Naoya Inamura, Daisuke Yoshida, Rikiya Onimaru, Hiroki Shirato, Satoshi Fukuda

Affiliation

¹ Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan. taki-s@hakochu-hp.gr.jp

PMID: 21964674
DOI: 10.1007/s10147-011-0308-1

Abstract

Concomitant radiotherapy and superselective arterial infusion of cisplatin for laryngeal cancer has shown excellent therapeutic outcomes. It is expected to be a reasonable treatment option for laryngeal cancer, especially in locally advanced cases.

MeSH terms

Adult
Aged
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Cisplatin / administration & dosage
Cisplatin / therapeutic use*
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Infusions, Intra-Arterial
Laryngeal Neoplasms / drug therapy*
Laryngeal Neoplasms / pathology
Laryngeal Neoplasms / radiotherapy*
Male
Middle Aged
Survival Analysis

Substances

Antineoplastic Agents
Cisplatin